Metal legend with lymphoma 'overwhelmed' by fan support

As previously reported, Black Sabbath legend Tony Iommi has been diagnosed with an unidentified form of lymphoma.

While a statement had been released by the band's publicist, only now has Iommi himself spoken out, through the following press release:

My fans, friends & colleagues:

I just want to say how overwhelmed I am with all your messages of support, thank you so much.

Well it’s not what I wanted for Christmas, that’s for sure, but now I can’t wait for the test results to come in and get going with the treatment.

It’s really good that the guys are coming over so that we can continue working on the album as things are going great in the studio.

Well, not much else to say at this time, so thanks again.

Bless you all,

Tony

Black Sabbath had a world tour set to begin in late May, and so far no changes have been made, although many speculate that at the very least, the beginning of the tour will be delayed.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap